Please try another search
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Michael J. Higgins | 62 | 2015 | Independent Chairman |
Teofilo David Raad | 54 | 2017 | President, CEO & Director |
Richard B. Moss | - | - | Member of Pulmazole Clinical Advisory Board |
Christopher H. Cabell | 54 | 2020 | Independent Director |
Stewart J. Tepper | - | - | Member of PUR3100 (DHE) Clinical Advisory Board |
Peter Wark | - | - | Member of Pulmazole Clinical Advisory Board |
Fernando Martinez | - | 2022 | Member of PUR1800 Clinical Advisory Board |
Cendrine Godet | - | - | Member of Pulmazole Clinical Advisory Board |
Jonathan Corren | - | - | Member of Pulmazole Clinical Advisory Board |
David A. Stevens | - | - | Member of Pulmazole Clinical Advisory Board |
David W. Denning | - | - | Member of Pulmazole Clinical Advisory Board |
William J. Calhoun | - | - | Chair of PUR1900 & PUR1800 Clinical Advisory Board |
Russell A. Settipane | - | - | Member of Pulmazole Clinical Advisory Board |
Ritesh Agarwal | - | - | Member of Pulmazole Clinical Advisory Board |
Peter J. Goadsby | - | - | Member of PUR3100 (DHE) Clinical Advisory Board |
Abraham J. Nagy | - | - | Member of PUR3100 (DHE) Clinical Advisory Board |
Wisla Wedzicha | - | - | Member of PUR1800 Clinical Advisory Board |
Richard P. Batycky | 56 | 2019 | Independent Director |
Todd Bazemore | 54 | 2020 | Independent Director |
Russell G. Clayton | 63 | - | Member of Pulmazole & PUR1800 Clinical Advisory Board |
Michael E. Wechsler | - | - | Member of Pulmazole Clinical Advisory Board |
Mario Castro | - | - | Member of Pulmazole Clinical Advisory Board |
Anand Varadan | 57 | 2021 | Independent Director |
Stephen Silberstein | - | - | Chair of PUR3100 (DHE) Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review